- Trials with a EudraCT protocol (44,349)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,349 result(s) found.
Displaying page 2,083 of 2,218.
EudraCT Number: 2017-001308-31 | Sponsor Protocol Number: PALG-AML1/2016 | Start Date*: 2017-06-27 |
Sponsor Name:Polish Adult Leukaemia Group (PALG) | ||
Full Title: A Polish Adult Leukemia Group (PALG) prospective, multicenter clinical trial to compare the efficacy of two standard induction therapies (DA-90 vs DAC) and two standard salvage regimens (FLAG-IDA ... | ||
Medical condition: The study will include newly diagnosed AML patients (other than acute promyelocytic leukemia); age 18-60 years, who are eligible for standard induction chemotherapy. The patients will be randomized... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: PL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003426-32 | Sponsor Protocol Number: DCOne-002 | Start Date*: 2017-12-11 | |||||||||||
Sponsor Name:DCprime bv | |||||||||||||
Full Title: AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DIFFERENT VACCINATION REGIMENS OF IMMUNOTHERAPY WITH ALLOGENEIC DENDRITIC CELLS, DCP-001, IN PATIENTS WIT... | |||||||||||||
Medical condition: The medical condition investigated are patients with acute myeloid leukemia in complete remission with persistent minimal residual disease and as such are at high risk of relapse. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) NO (Completed) SE (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001365-26 | Sponsor Protocol Number: AN-IGN3321 | Start Date*: 2014-08-21 | |||||||||||
Sponsor Name:Anthera Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with IgA Nephropathy | |||||||||||||
Medical condition: IgA Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) DE (Completed) IT (Prematurely Ended) HU (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004540-29 | Sponsor Protocol Number: malin2.0 | Start Date*: 2013-05-24 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Injection treatment of ranula with OK 432 - A prospective, randomized, placebo controlled, double-blind study | ||
Medical condition: Patients with ranula. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003099-28 | Sponsor Protocol Number: BIONIKK | Start Date*: 2017-02-08 |
Sponsor Name:A.R.T.I.C (Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie) | ||
Full Title: A Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer | ||
Medical condition: Naïve metastatic Kidney cancer(mRCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004053-88 | Sponsor Protocol Number: EuroNet-PHL-C2 | Start Date*: 2015-07-01 |
Sponsor Name:Justus-Liebig-University Giessen | ||
Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents | ||
Medical condition: Hodgkin lymphoma in children and adolescents | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) BE (Completed) AT (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended) NL (Completed) DK (Prematurely Ended) FR (Ongoing) PL (Prematurely Ended) FI (Completed) GB (GB - no longer in EU/EEA) SE (Completed) NO (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002053-29 | Sponsor Protocol Number: 03042012 | Start Date*: 2012-08-10 | |||||||||||
Sponsor Name:Karolinska Institutet and University Hospital | |||||||||||||
Full Title: PET/CT-biopsi study A PET/CT biopsy sub study in patients who have given informed consent to participate in a randomized, dubbel blind, placebo controlled phase III trial with Capecitabine +/- So... | |||||||||||||
Medical condition: Morphological verifications of metastatic lesions, PET Ribonucleic Acid (RNA)-expression study in subjects with locally advance or metastatic HER2-negative breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003078-10 | Sponsor Protocol Number: SPCG 16 | Start Date*: 2011-11-02 | |||||||||||
Sponsor Name:SPCG | |||||||||||||
Full Title: SPCG 16 Sensi-cab Randomized phase III trial comparing cabazitaxel in combination with hormone therapy to hormone therapy alone in metastatic prostate cancer | |||||||||||||
Medical condition: Patients diagnosed with metastatic or high risk(PSA>100 or N1) prostate cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001557-85 | Sponsor Protocol Number: 5.0 | Start Date*: 2011-08-22 | |||||||||||
Sponsor Name:Nordic Lymphoma Group | |||||||||||||
Full Title: NLG-MCL5 (MARiT) Rituximab, High Dose Ara-C and Dexamethasone Followed by BEAM in Mantle Cell Lymphoma Patients <66 years A Nordic Lymphoma Group and British Lymphoma Group Phase-II Trial | |||||||||||||
Medical condition: Mantle cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Temporarily Halted) DK (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005905-21 | Sponsor Protocol Number: AOI/2008/EJ-02 | Start Date*: 2009-04-17 |
Sponsor Name:CHU de Nîmes | ||
Full Title: Cinétique du taux de protéasome circulant au cours du traitement par inhibiteur du protéasome (bortézomib, Velcade®) au cours du myélome multiple | ||
Medical condition: Myélome multiple | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006874-14 | Sponsor Protocol Number: Local/2008/BL-01 | Start Date*: 2009-04-09 |
Sponsor Name:CHU de Nîmes | ||
Full Title: Aspects Pharmacogénétiques et Pharmacocinétiques de la réponse à la CHimiothérapie d’induction par Docetaxel, Cisplatine et 5-Fluorouracile (TPF), des cancers ORL | ||
Medical condition: carcinomes épidermoïdes des voies aéro-digestives supérieures | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002724-33 | Sponsor Protocol Number: RECHMPL19-0069 | Start Date*: 2019-11-15 |
Sponsor Name:University Hospital of Montpellier | ||
Full Title: Eosinophil-driven corticotherapy for patients hospitalized for COPD exacerbation: a double-blind, randomized, controlled trial | ||
Medical condition: The study population corresponds to patients hospitalized for COPD exacerbation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004403-12 | Sponsor Protocol Number: APHP190871 | Start Date*: 2020-10-26 |
Sponsor Name:ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS | ||
Full Title: Phase II multicenter study of talimogene laherparepvec in classic or endemic Kaposi sarcoma Kapvec Study | ||
Medical condition: The study will provide an overview of efficacy and safety of talimogene laherparepvec in classic and endemic KS | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003042-20 | Sponsor Protocol Number: ET21-169 | Start Date*: 2022-06-21 |
Sponsor Name:Centre Léon Bérard | ||
Full Title: PARPi-PANC - A multicentric, single arm, phase II trial assessing the efficacy of niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer | ||
Medical condition: Patients with metastatic homologous repair-deficient pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017126-39 | Sponsor Protocol Number: PHRCI/2009/EN-01 | Start Date*: 2010-04-15 |
Sponsor Name:CHU de Nîmes | ||
Full Title: Qualité du réveil après chirurgie bariatrique : Xénon versus desflurane | ||
Medical condition: chirurgie bariatrique | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001215-37 | Sponsor Protocol Number: RG_16_211 | Start Date*: 2018-03-19 |
Sponsor Name:University of Birmingham | ||
Full Title: A pivotal, international, randomised, double-blind, efficacy and safety trial of sodium valporate in paediatric and adult patients with Wolfram Syndrome | ||
Medical condition: Wolfram syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003455-35 | Sponsor Protocol Number: MK-8835-059 | Start Date*: 2019-09-26 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | |||||||||||||
Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in Pediatric Participants (ages 10 to ... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Trial now transitioned) PL (Trial now transitioned) FR (Prematurely Ended) BE (Completed) Outside EU/EEA IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003751-42 | Sponsor Protocol Number: ICH-013-UroNEOadI | Start Date*: 2022-01-25 | |||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: Randomized phase III clinical trial of Neo-Adjuvant Intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve vesical neoplasms. | |||||||||||||
Medical condition: Patients with primary treatment-naïve vesical neoplasms. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002647-29 | Sponsor Protocol Number: PCIA_203/18 | Start Date*: 2019-03-27 | |||||||||||
Sponsor Name:PCI Biotech AS | |||||||||||||
Full Title: A Multi-Centre, Randomised, Open-Label, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/... | |||||||||||||
Medical condition: Inoperable Cholangiocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NO (Completed) SE (Completed) ES (Prematurely Ended) DK (Completed) FI (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002738-19 | Sponsor Protocol Number: ESR-17-13092 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: NAsal Polyps: inflammatory & molecular Phenotyping of REsponders to Benralizumab | |||||||||||||
Medical condition: Patients with chronic rhinosinusinusitis with nasal polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
